PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) said it will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026, placing fresh attention on the Philadelphia-based biotechnology company as it pushes forward with experimental cell therapies aimed at autoimmune diseases.
The company said the discussion is scheduled for Thursday, February 12, at 9:30 a.m. Eastern Time in New York. A live webcast of the presentation will be available in the News and Events section of the company’s website at www.cabalettabio.com, with replays accessible for 30 days.
Cabaletta Bio is a late-stage clinical biotechnology company focused on developing what it describes as the first curative targeted cell therapies specifically designed for patients with autoimmune disorders. Its research centers on engineered T cell therapies intended to deliver deep and durable treatment effects across a broad range of diseases.
The company’s CABA platform includes two complementary strategies aimed at advancing cell-based therapies for autoimmunity. Its lead approach, known as CARTA, prioritizes the development of rese-cel, a fully human CD19-CAR T cell investigational therapy containing a 4-1BB co-stimulatory domain.
Rese-cel is being evaluated in the RESET clinical development program, which spans multiple therapeutic areas, including rheumatology, neurology, and dermatology. The program is designed to explore whether engineered T cells can restore immune tolerance and potentially offer long-lasting relief for patients with chronic autoimmune conditions.
Cabaletta Bio is headquartered in Philadelphia, where its research laboratories are also located, as the company continues to advance its clinical pipeline while engaging investors and industry leaders at major biotechnology forums.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.